Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis

Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis

Large randomized clinical trials and prior meta-analyses indicate that second-generation BCR-ABL tyrosine kinase inhibitors (TKIs) improve surrogate biomarkers in patients with chronic myeloid leukemia (CML) without providing survival benefits. The objective is to evaluate the long-term efficacy and...

Full description

Bibliographic Details
Main Authors:	Hélène Haguet, Carlos Graux, François Mullier, Jean-Michel Dogné, Jonathan Douxfils
Format:	Article
Language:	English
Published:	MDPI AG 2020-05-01
Series:	Cancers
Subjects:	protein kinase inhibitors overall survival meta-analysis leukemia myelogenous chronic BCR-ABL positive
Online Access:	https://www.mdpi.com/2072-6694/12/5/1242

Similar Items

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
by: Peng Zeng, et al.
Published: (2020-09-01)

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
by: Hélène Haguet, et al.
Published: (2018-01-01)

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study
by: Hélène Haguet, et al.
Published: (2020-07-01)

Isolated monocytosis was the flag preceding abnormalities in other parameters of complete blood counts in chronic myeloid leukemia with e1a2 (minor, P190) chimeric transcripts
by: Jae Won Yun, et al.
Published: (2019-03-01)

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice
by: Antonio Almeida, et al.
Published: (2019-08-01)

Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
by: Maria Juracy Petrola, et al.
Published: (2012-01-01)

Perfil do estresse oxidativo em pacientes portadores de Leucemia MielÃide CrÃnica
by: Maria Juracy Solon Petrola
Published: (2011)

Detection of derivative 9 deletion by BCR-ABL fluorescence in-situ hybridization signal pattern to evaluate treatment response in CML patients
by: Bakshi Sonal R., et al.
Published: (2009-01-01)

Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia
by: Begoña San José Ruiz, et al.
Published: (2015-01-01)

Detection of p190BCR-ABL AND p210BCR-ABL fusion transcripts in patients with chronic myeloid leukemia (CML) using qualitative RT-PCR
by: Aya Bonilla, Carlos Alberto, et al.
Published: (2014-10-01)

Use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML)
by: C. B. Almeida, et al.
Published: (2016-11-01)

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
by: Melissa Pereira Machado, et al.
Published: (2011-06-01)

Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis
by: Poonam P Jain, et al.
Published: (2012-01-01)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
by: Xiaoying Lan, et al.
Published: (2016-11-01)

Deep and early molecular response induced by nilotinb in a newly diagnosed patient with chronic myeloid leukemia (CML)
by: Antonella Russo Rossi
Published: (2015-10-01)

Chronic myeloid leukemia: past, present, future
by: Patricia Weinschenker Bollmann, et al.
Published: (2011-06-01)

Análisis de costo-efectividad de nilotinib, dasatinib e imatinib como terapia de primera línea en leucemia mieloide crónica en Colombia, 2012
by: Martín Romero, et al.
Published: (2014-03-01)

Trends in mortality of adult patients diagnosed with myeloid leukemia from 1994 to 2011 in southeastern Brazil
by: Fernando Callera, et al.
Published: (2015-02-01)

Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy
by: Stamatović Dragana, et al.
Published: (2012-01-01)

Several different cytogenetic clones arising during treatment of Philadelphia positive chronic myeloid leukemia with tyrosine kinase inhibitors lead to the progression into Philadelphia negative acute myeloid leukemia
by: Denčić-Fekete Marija, et al.
Published: (2021-01-01)

Dasatinib: ten years of clinical practice worldwide
by: K. M. Abdulkadyrov, et al.
Published: (2016-03-01)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
by: Maria Stella Pennisi, et al.
Published: (2019-08-01)

Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
by: Mousa Vatanmakanian, et al.
Published: (2019-04-01)

Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients
by: Maria de Lourdes Lopes Ferrari Chauffaille, et al.
Published: (2015-02-01)

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib
by: Ćojbašić Irena, et al.
Published: (2011-01-01)

The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era
by: Ilana Zalcberg Renault, et al.
Published: (2011-12-01)

Application of PI-deconvolution to the screening of protein ligand combinatorial libraries using the yeast-two-hybrid assay
by: Aparicio de Navaraez, Alberto
Published: (2008)

Chronic myelogenous leukemia on target
by: Veronika Némethová, et al.
Published: (2018-07-01)

Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome
by: Daiana Landenberger de Carvalho, et al.
Published: (2012-01-01)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
by: Roberta Bitencourt, et al.
Published: (2011-12-01)

Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Derivatives: Optimization of Anti-ABL Kinase Activity
by: Halil I. Ciftci, et al.
Published: (2019-09-01)

Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital
by: Samuel Roosevelt Campos dos Reis, et al.
Published: (2013-06-01)

Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance
by: Xiaoyun Lu, et al.
Published: (2017-01-01)

Chronic Myeloid Leukemia with b3a3 (e14a3) Fusion: A Rare BCR/ABL Rearrangement Presenting with Thrombocytosis – Does MTHFR Polymorphism Matter
by: Mohammad Muhsin Chisti, et al.
Published: (2018-07-01)

Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia
by: Ilana de França Azevedo, et al.
Published: (2014-10-01)

Patients' perceptions about diagnosis and treatment of chronic myeloid leukemia: a cross-sectional study among Brazilian patients
by: Nelson Hamerschlak, et al.

Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety
by: Mehlika Dilek Altıntop, et al.
Published: (2017-12-01)

Leucemia mieloide crónica, estado del arte Myeloid cronic leukemia, state of the art
by: Luz Aída Rey, et al.
Published: (2009-08-01)

Concomitant BCR-ABL1 positive chronic myelogenous leukemia emerging in a patient with MPL W515L associated primary myelofibrosis
by: Juan C. Gomez-Gelvez, MD, et al.
Published: (2016-03-01)

Altered mRNA Metabolism in Chronic Myelogenous Leukemia: Loss of MicroRNA-328 Decoy Activity is Important for Blastic Transformation of Leukemic Progenitors
by: Eiring, Anna Marie
Published: (2009)